BCL2 and Miyoshi myopathy: Venetoclax has demonstrated remarkable efficacy in MM, particularly in patients harboring specific genetic subtypes such as the t(11;14) [47–49] and t(6;14) [50] translocations, which are associated with elevated Bcl-2 expression [51–53].